middle.news
How Radiopharm Theranostics’ $35M Raise Fuels Ambitious Clinical Pipeline Expansion
1:24pm on Friday 27th of February, 2026 AEDT
•
Healthcare
Read Story
How Radiopharm Theranostics’ $35M Raise Fuels Ambitious Clinical Pipeline Expansion
1:24pm on Friday 27th of February, 2026 AEDT
Key Points
44% increase in net loss to $27 million for H1 FY2026
Completed $35 million institutional placement boosting cash to $34.5 million
Positive interim Phase 2b data for RAD 101 brain metastases imaging
Advancement of Phase 1 trials for HER2, PD-L1, B7-H3, and prostate cancer candidates
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
RADIOPHARM THERANOSTICS (ASX:RAD)
OPEN ARTICLE